CARNITOR injection is labeled for specific carnitine-deficiency conditions and for intravenous administration. This does not establish an approved intramuscular performance or fat-loss use.[1]
- Jurisdiction
- United States
- Product
- CARNITOR levocarnitine injection
- Indication
- Secondary carnitine deficiency from inborn metabolic errors; prevention/treatment of dialysis-associated deficiency
- Record date
- 2026-09-08
- Oral dietary studies and intravenous treatment of deficiency do not verify intramuscular products.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.
· Independently reopened the current DailyMed label pinned to version 19 (Effective Time 2023-11-20). Confirmed both indication statements verbatim ("acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency"; "prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis"), the hypersensitivity warning, and "Injection is administered intravenously." Confirmed the label contains no mention of intramuscular administration anywhere. No correction needed; no qualified clinical review.
· Currency check for the regulatory-currency batch. The cited label URL pins one version, so the DailyMed version history and the unpinned page for the same Set ID were read to confirm that the pinned version is still the current one. It is. The recorded date, the claim text and the sources are unchanged. Independent editorial review pending; no qualified clinical review.